Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2018 Nov 5:2018:9450754.
doi: 10.1155/2018/9450754. eCollection 2018.

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy

Irene S Yu  1 , Winson Y Cheung  2
Affiliations
Review

Metastatic Colorectal Cancer in the Era of Personalized Medicine: A More Tailored Approach to Systemic Therapy

Irene S Yu et al. Can J Gastroenterol Hepatol. .

Abstract

Colorectal cancer is the second most common malignancy diagnosed in Canada. Despite declining incidence and mortality rates in recent years, there is still a significant number of cases that are metastatic at presentation. Fluoropyrimidine-based chemotherapy was the backbone of colorectal cancer treatment, but the addition of irinotecan and oxaliplatin to form combination regimens has significantly improved overall survival. In the past decade, the development of novel biologic agents including therapies directed against vascular endothelial growth factor and epidermal growth factor receptor has further altered the landscape of metastatic colorectal cancer treatment. However, clinical trials have demonstrated that not all patients respond to these therapies similarly and consideration must be given to individual patient- and tumor-related factors. A more tailored and biomarker driven approach to treatment selection can optimize outcomes and avoid unnecessary adverse effects. In this review article, we offer a comprehensive overview of the panel of clinical- and tumor-associated characteristics that influence treatment decisions in metastatic colorectal cancer and how this sets the foundation for a more personalized treatment strategy in oncology.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

See all "Cited by" articles

References

    1. Canadian Cancer Society’s Advisory Committee on Cancer Statistics, Canadian Cancer Statistics 2017, Canadian Cancer Society, Toronto, Canada. - DOI
    1. National Cancer Institute Surveillance, Epidemiology, and End Results program, “Cancer Stat Facts: Colorectal Cancer,” https://seer.cancer.gov/statfacts/html/colorect.html, (retrieved March 1, 2018)
    1. Scheithauer W., Rosen H., Kornek G.-V., Sebesta C., Depisch D. Randomised comparison of combination chemotherapy plus supportive care with supportive care alone in patients with metastatic colorectal cancer. British Medical Journal. 1993;306(6880):752–755. doi: 10.1136/bmj.306.6880.752. - DOI - PMC - PubMed
    1. Heinemann V., von Weikersthal L. F., Decker T., et al. Folfiri plus cetuximab versus folfiri plus bevacizumab as first-line treatment for patients with metastatic colorectal cancer (fire-3): a randomised, open-label, phase 3 trial. The Lancet Oncology. 2014;15:1065–1075. doi: 10.1016/s1470-2045(14)70330-4. - DOI - PubMed
    1. Poon M. A., O'Connell M. J., Moertel C. G., et al. Biochemical modulation of fluorouracil: Evidence of significant improvement of survival and quality of life in patients with advanced colorectal carcinoma. Journal of Clinical Oncology. 1989;7(10):1407–1418. doi: 10.1200/JCO.1989.7.10.1407. - DOI - PubMed

MeSH terms

Substances